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The emerging roles of intestinal macrophages  
in sickness and in health
Abstract
The immune system in the intestine represents a unique environment that 
can quickly respond to harmful pathogens, but it remains tolerant to antigens 
from food and commensal bacteria. This balance between protective im-
munity and tolerance is largely dependent on the mononuclear phagocytes 
in the intestine, such as macrophages. Intestinal macrophages, unlike other 
macrophage populations in the body, are hypo-responsive to stimuli although 
they originate from fully responsive blood monocytes. The intestinal environ-
ment seems to instruct monocytes to mute their function upon arrival to the 
gut in order to adapt to the antigen-rich environment. While their main 
role in the healthy gut is to maintain homeostasis, in disease macrophage 
phenotype and function is changed and these cells become the drivers of in-
flammation and disease progression.
INTRoduCTIoN
Immediately after birth, the intestine is colonised by a vast microbial community that reaches 1013-1014 bacteria per gram of luminal con-
tent (1, 2). Alongside the exposure to these commensal bacteria the in-
testine is also exposed to a variety of food proteins and pathogenic organ-
isms, which means that it constantly encounters more antigens that any 
other part of the body (1). In order to protect against infection but at the 
same time avoid the unnecessary inflammatory responses to beneficial 
microbiota and food, the immune system in the intestine has evolved 
into the largest and most complex part of the host immune system. The 
homeostasis here is balanced through a strict hierarchy of mechanisms 
that include many immune and non-immune cells. One of the key 
regulators of homeostasis in the intestine are macrophages. This review 
describes the adaptations of intestinal macrophages to their antigen-rich 
environment and a different role they play in a healthy and diseased state.
ThE uNIquE PRoPERTIES of INTESTINAl 
mACRoPhAGES
Most of the macrophages in the body are effector cells which get 
activated by molecular patterns expressed on different pathogens 
through Toll-like receptors (TLR). Upon activation these cells increase 
the secretion of cytokines and other pro-inflammatory mediators, in-
crease the expression of co-stimulatory molecules (such as CD80, CD86, 
CD40) and exhibit enhanced killing of microorganisms (3).The intesti-
Received May 26, 2014.
 Overview
Maja Kristek and Christine E. Loscher The emerging roles of intestinal macrophages in sickness and in health
126 Period biol, Vol 116, No 2, 2014.
nal macrophages, however, display somewhat different 
function and phenotype than classically described mac-
rophages. They are highly unresponsive to any TLR 
stimulation (4-6) and do not produce pro-inflammatory 
cytokines (7) or other pro-inflammatory mediators, such 
as nitric-oxide (NO) or reactive oxygen species (ROS) (8, 
9). Furthermore, they express only low levels of co-stim-
ulatory molecules, such as CD80, CD86 and CD40 (10). 
They do produce anti-inflammatory cytokine IL-10, con-
stitutively and in response to TLR ligation (11) and, as 
shown recently, they produce pro-inflammatory TNF-a 
even in a steady state, but this does not lead to inflamma-
tion (12). Despite this anergy, intestinal macrophages 
exhibit strong phagocytic and bacteriocidal activity which 
allows them to efficiently clear bacteria, cellular debris 
and foreign material (13). The differences between intes-
tinal macrophages and other macrophages are sum-
marised in Table 1. Thanks to these adaptations intestinal 
macrophages are able to survey the gut without mounting 
an immune response to beneficial antigens coming from 
commensal bacteria and food.
TAble 1
Phenotypic comparison of macrophage 
populations
Difference between intestinal macrophages 















NO production – +
ROS production – +
IL-10 production + +
TNF-a production + +
how do INTESTINAl mACRoPhAGES 
GET ThEIR uNIquE PRoPERTIES?
All tissue macrophages are derived from bone marrow 
stem cells through a highly regulated cascade of events. In 
the bone-marrow, a combination of cytokines that include 
IL-1, IL-3 and IL-6 together with granulocyte/macro-
phage colony stimulating factor (GM-CSF) and macro-
phage-colony stimulating factor (M-SCF) induce prolif-
eration of a monocyte precursor into a monoblast, then a 
promonocyte and finally a monocyte (4). After leaving the 
bone marrow, monocytes enter the blood, where they cir-
culate for days before migrating into tissue (14). It is be-
lieved that there are two different populations of mono-
cytes; one that migrates and replenishes macrophages in 
the resting tissue and one that is recruited during inflam-
mation (15). The first population was termed „resident” 
monocytes. „Resident” monocytes are non-inflammatory 
and inert to stimuli (15). The second population are termed 
„inflammatory” monocytes and unlike „resident” mono-
cytes they are fully responsive to stimulation and home to 
inflamed tissue (15).Because of their distinctive, non-in-
flammatory features, intestinal macrophages were thought 
to derive from „resident” monocytes. Surprisingly, experi-
ments combining resident cell ablation with precursor cell 
transfer have shown that resident intestinal macrophages, 
actually, derive from „inflammatory” monocytes (16, 17). 
Once they arrive in the gut these „inflammatory” mono-
cytes then adapt to the gut environment by acquiring a 
non-inflammatory gene expression signature (12). In other 
words, it seems that the intestinal environment is educat-
ing monocytes upon their arrival to the gut, making them 
match the dynamic nature in which they have arrived.
RolE of INTESTINAl mACRoPhAGES 
IN A hEAlThy STATE
Because of their hypo-responsiveness to stimuli and in-
ability to mount an inflammatory response, the only role 
of intestinal macrophages was thought to be phagocytosis 
of apoptotic cells and debris. However, they have been 
shown to be important for intestinal homeostasis as deple-
tion of macrophages leads to intestinal inflammation (18). 
One of their homeostatic-inducing roles is the regulation 
of epithelial cell integrity (Figure 1A). Intestinal macro-
phages produce prostaglandin E2 and promote survival 
and proliferation of epithelial progenitor cells during co-
lonic wound healing (19). Also, they produce cyclo-oxy-
genase 2 (COx2) which has been linked with anti-inflam-
matory effects, as myeloid cell specific COx2 knockout 
mice have increased expression of pro-inflammatory cyto-
kines, such as IL-6, TNF-a and IFN-g, compared to wild 
type (20). Furthermore, intestinal macrophages are close-
ly associated with epithelium and can extending processes 
across the epithelial layer into the intestinal lumen and 
sample bacteria (21, 22). Information they gain this way 
can instruct and recruit other immune cells. Indeed, mac-
rophages in the intestine have been shown to maintain 
regulatory T-cells which are also important for the suppres-
sion of immune response upon exposure to food antigen. 
Therefore, both cells work together to establish oral toler-
ance and promote gut homeostasis (Figure 1A) (23).
A dIffERENT fACE of mACRoPhAGES 
IN INflAmmAToRy bowEl dISEASE
Inflammatory bowel disease (IBD) is an inflammatory 
disorder of the gastrointestinal tract characterised by an 
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abnormal immune response to antigens of the intestinal 
content that leads to a persistent inflammatory state (24). 
Two major forms of IBD are Crohn’s disease and ulcer-
ative colitis, distinguished by the area they affect. While 
ulcerative colitis exclusively effects the colon, Crohn’s dis-
ease can affect the whole gastrointestinal tract, but is 
mainly localised to the colon and ileum (25). The exact 
cause of IBD remains poorly understood, however differ-
ent environmental factors are considered risk factors for 
IBD, such as smoking, diet, drugs, stress and enteric flora 
(26). Both ulcerative colitis and Crohn’s disease are char-
acterised by the disruption of the epithelial cell barrier and 
the dysfunction of the immune system.Disruption of in-
testinal epithelial barrier in IBD allows the invasion of 
commensal bacteria. This leads to influx of inflammatory 
cells and their constant activation. Indeed, patients with 
active IBD have an increased number of macrophages in 
the inflamed intestinal mucosa (27) and these macro-
phages display a different phenotypic and functional pro-
file than under homeostatic conditions (Figure 1B). Mac-
rophages in IBD patients display increased levels of 
co-stimulatory receptors, such as CD40, CD80 and 
CD86 which enables the crosstalk and activation of T-
cells (28). This is coupled with an increased production 
of pro-inflammatory cytokines, such as IL-12 and IL-23 
(6). IL-12 drives IFN-g production from T-cells, which 
then in turn increases macrophage activation and also 
increases epithelial cell permeability (6). IL-23 promotes 
a development of a CD4+ phenotype characterised by the 
production of IL-17, called Th17 cells, which are involved 
in the pathogenesis of IBD (6). Macrophages in IBD are 
also a main source of TNF-a, which is considered to be 
a „master regulator” of pro-inflammatory cytokine pro-
duction. It has a pivotal role in orchestrating the produc-
tion of a pro-inflammatory cytokine cascade and there-
fore drives the disease (29). Furthermore, macrophages in 
the IBD show increased expression of pathogen-recognis-
ing receptors, such as TLR2 and TLR4 and also trigger-
ing receptor expressed on myeloid cells (TREM)-1 which 
triggers the synthesis and secretion of inflammatory fac-
tors (7, 30). Engagement of TREM-1 leads to increased 
secretion of IL-1b, IL-6 and IL-8 (31). This pro-inflam-
matory response leads to epithelial apoptosis, necrosis, 
formation of granuloma and fibrosis (32). Expression of 
tissue degrading cathepsins by intestinal macrophages has 
also been seen in IBD (33), together with an increased 
release of nitric oxide and oxygen radicals that further 
contribute to macrophage-dependent tissue damage (34).
While macrophages in the inflamed intestine show an 
enhanced pro-inflammatory phenotype, their ability to 
eradicate intracellular pathogens is decreased as their 
phagocytosis is significantly reduced (35). This probably 
accounts for recurrent infection in IBD patients with 
pathogens that directly target macrophages, such as My-
cobacterium paratuberculosis (36).Some of the disruptions 
in macrophage signalling are also reported to contribute 
to intestinal inflammation. Selective disruption in signal 
Figure 1. Role of intestinal macrophages in a healthy state (A) and in disease (B). In healthy intestine macrophages protect the epithelial 
cells barrier, support the induction of regulatory T-cells and destroy pathogens that breach the epithelial layer. In this way they maintain ho-
meostasis and oral tolerance (A). In disease macrophages lose their homeostatic properties, show an enhanced pro-inflammatory phenotype and 
drive tissue injury and disease progression (B).
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transducer and activator of transcription (STAT)3 signal-
ling in macrophages leads to impaired production of anti-
inflammatory IL-10 and spontaneous development of 
colitis in mice (37). The mutant form of nucleotide-bind-
ing oligomerization domain-containing protein (NOD)2, 
associated with Crohn’s disease, is also expressed on mac-
rophages and therefore may contribute to disease pathol-
ogy (38).
CoNCluSIoN
Intestinal macrophages show distinct phenotypic and 
functional features in a healthy state and in disease. In 
healthy state, intestinal macrophages are highly anti-in-
flammatory cells, capable of destroying pathogens with-
out initiating an immune response and damaging the 
surrounding tissue. Thanks to these features they main-
tain an immunosuppressive milieu in the gut which coun-
teracts the constant influx of antigens from the food and 
commensal bacteria. In disease, however, the immuno-
suppressive balance is disturbed. These anti-inflammato-
ry macrophages suddenly lose their homeostatic proper-
ties and become sensitised to gut microbes. This is 
followed by an increased production of pro-inflammato-
ry mediators and activation of surrounding immune cells. 
Previously immunologically inert macrophages now be-
come drivers of pathogenesis and tissue destruction. It is 
unclear at what point this functional switch between ho-
meostatic and inflammatory properties occurs and what 
is driving it. Identification of key factors that influence 
macrophages in a healthy state and disease, together with 
better understanding of macrophage plasticity in the gut, 
is of a great importance if we want to find new targets for 
the treatment of gut inflammation. Hopefully by return-
ing macrophages into their original, homeostatic role we 
can restore the physiological balance and attenuate in-
flammation, rather than just targeting symptoms of dis-
ease as currently available therapies do.
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